On July 10, CSPC Pharmaceutical rose 3.19% in regular trading, trading at 8.14 HKD/share, with turnover of HKD 219 million. The move came as the broader pharmaceutical sector rallied alongside a cluster of recent company-specific catalysts.

On the news front, CSPC recently announced a strategic collaboration with AstraZeneca on siRNA drug discovery and extrahepatic targeted delivery platforms, with a deal valued at up to USD 1.77 billion, including a USD 30 million upfront payment. Additionally, the company's ADC drug SYS6043 was granted breakthrough therapy designation by China's NMPA for platinum-resistant ovarian cancer. Subsidiary CSPC Innovation also resubmitted its Hong Kong listing application on June 18.

At the sector level, pharmaceutical stocks broadly strengthened, with Asymchem up 5.64%, Hengrui Pharma up 3.33%, Hansoh Pharma up 2.82%, and Luye Pharma up 1.57%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)